MX2018015787A - Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado. - Google Patents

Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado.

Info

Publication number
MX2018015787A
MX2018015787A MX2018015787A MX2018015787A MX2018015787A MX 2018015787 A MX2018015787 A MX 2018015787A MX 2018015787 A MX2018015787 A MX 2018015787A MX 2018015787 A MX2018015787 A MX 2018015787A MX 2018015787 A MX2018015787 A MX 2018015787A
Authority
MX
Mexico
Prior art keywords
polyacrylic acid
acid polymer
linear
immunogenic formulations
novel immunogenic
Prior art date
Application number
MX2018015787A
Other languages
English (en)
Inventor
Rigaut Guillaume
Guy André Lucien Parisot Alexis
De Luca Karelle
Michele Pierrette Andreoni Christine
REMOLUE Lydie
GARINOT Marie
Francois Cotte Jean-
Probeck-Quellect Patricia
Haensler Jean
Chambon Véronique
TALAGA Philippe
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2018015787A publication Critical patent/MX2018015787A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/04—Acids; Metal salts or ammonium salts thereof
    • C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F6/00—Post-polymerisation treatments
    • C08F6/001—Removal of residual monomers by physical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona formulaciones inmunológicas y de vacuna novedosas que comprenden un adyuvante de polímero de ácido poliacrílico no reticulado recientemente aplicado. Los adyuvantes se pueden combinar con una amplia variedad de inmunógenos para producir vacunas que son seguras y efectivas cuando se administran a una amplia gama de animales objetivo. Los inmunógenos pueden incluir, pero no están limitados a: patógenos inactivados, patógenos atenuados, subunidades, vectores de expresión recombinantes, plásmidos o combinaciones de los mismos. Los animales pueden incluir, pero no están limitados a: humanos, murino, caninos, felinos, equinos, porcinos, ovinos, caprinos y bovinos.
MX2018015787A 2016-06-17 2017-06-15 Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado. MX2018015787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351492P 2016-06-17 2016-06-17
PCT/US2017/037745 WO2017218819A1 (en) 2016-06-17 2017-06-15 Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants

Publications (1)

Publication Number Publication Date
MX2018015787A true MX2018015787A (es) 2019-04-22

Family

ID=59295306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015787A MX2018015787A (es) 2016-06-17 2017-06-15 Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado.

Country Status (10)

Country Link
US (1) US11554170B2 (es)
EP (1) EP3471760A1 (es)
JP (1) JP7018941B2 (es)
KR (1) KR20190044052A (es)
CN (1) CN109475615B (es)
AU (1) AU2017286727B2 (es)
BR (1) BR112018076015A8 (es)
CA (1) CA3027877A1 (es)
MX (1) MX2018015787A (es)
WO (1) WO2017218819A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002810A (es) * 2017-09-13 2020-07-21 Sanofi Pasteur Composicion inmunogenica de citomegalovirus humano.
MX2020010199A (es) 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
JP2021519599A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
CN112512565A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性流感-铁蛋白多肽
WO2019195316A1 (en) 2018-04-03 2019-10-10 Sanofi Ferritin proteins
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
CN109134724A (zh) * 2018-07-24 2019-01-04 石家庄哈顿生物技术有限公司 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法
WO2020142778A1 (en) * 2019-01-04 2020-07-09 Boehringer Ingelheim Animal Health USA Inc. Attenuated bordetella bronchiseptica strains, oral vaccines containing the attenuated strains, and methods of making & use thereof
WO2020205986A1 (en) 2019-04-02 2020-10-08 Sanofi Antigenic multimeric respiratory syncytial virus polypeptides
CN113444743A (zh) * 2021-06-22 2021-09-28 贵州大学 含佐剂基因的羊支原体肺炎二价核酸疫苗的构建方法
WO2023120535A1 (ja) * 2021-12-20 2023-06-29 東興薬品工業株式会社 ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
NZ215069A (en) 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
WO1989007143A1 (en) 1988-01-29 1989-08-10 Chiron Corporation Recombinant cmv neutralizing proteins
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
KR100374295B1 (ko) 1993-02-08 2003-12-24 바이엘 코포레이션 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
EP1651265B1 (en) 2003-07-24 2008-04-23 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
EP2534205B1 (en) * 2010-02-12 2016-05-04 Rhodia Operations Rheology modifier compositions and methods of use
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions

Also Published As

Publication number Publication date
EP3471760A1 (en) 2019-04-24
BR112018076015A8 (pt) 2022-06-28
US11554170B2 (en) 2023-01-17
JP2019524873A (ja) 2019-09-05
BR112018076015A2 (pt) 2019-03-26
CN109475615B (zh) 2023-04-07
CA3027877A1 (en) 2017-12-21
WO2017218819A1 (en) 2017-12-21
AU2017286727B2 (en) 2024-02-08
KR20190044052A (ko) 2019-04-29
US20170360923A1 (en) 2017-12-21
JP7018941B2 (ja) 2022-02-14
AU2017286727A1 (en) 2019-01-31
CN109475615A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
MX2018015787A (es) Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado.
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
BR112017005833A2 (pt) vacinas recombinantes fmdv e seus usos
BR112016028816A8 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
MX2017014538A (es) Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112012023852A2 (pt) vacinas recombinantes do vírus da língua azul e usos das mesmas
EA201800148A1 (ru) Оспенная вакцина для лечения рака
BR112018003967A2 (pt) tratamento de hipersensibilidade à picada de inseto
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
GB2539148A (en) Vaccine compositions
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
EA201892003A1 (ru) Лечение атопического дерматита собак
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
NZ743236A (en) Fmdv and e2 fusion proteins and uses thereof
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
MX2017014666A (es) Metodos de inmunización contra clostridium difficile.
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
MX2019014450A (es) Vacuna contra la enteritis necrotica en aves de corral.
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof